Metered Dose Inhaler Devices-Medical Devices Pipeline Assessment, 2017

Metered Dose Inhaler Devices-Medical Devices Pipeline Assessment, 2017


  • Products Id :- GDME0341EPD
  • |
  • Pages: 119
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Metered Dose Inhaler Devices-Medical Devices Pipeline Assessment, 2017

Summary

GlobalData's Medical Devices sector report, "Metered Dose Inhaler Devices-Medical Devices Pipeline Assessment, 2017" provides an overview of Metered Dose Inhaler Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Metered Dose Inhaler Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

Extensive coverage of the Metered Dose Inhaler Devices under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Metered Dose Inhaler Devices and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment / industry

Reasons to buy

The report enables you to-

Formulate significant competitor information, analysis, and insights to improve R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Metered Dose Inhaler Devices under development

Develop market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

In-depth analysis of the product's current stage of development, territory and estimated launch date



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Introduction 6

2.1 Metered Dose Inhaler Devices Overview 6

3 Products under Development 7

3.1 Metered Dose Inhaler Devices-Pipeline Products by Stage of Development 7

3.2 Metered Dose Inhaler Devices-Pipeline Products by Territory 8

3.3 Metered Dose Inhaler Devices-Pipeline Products by Regulatory Path 9

3.4 Metered Dose Inhaler Devices-Pipeline Products by Estimated Approval Date 10

3.5 Metered Dose Inhaler Devices-Ongoing Clinical Trials 11

4 Metered Dose Inhaler Devices-Pipeline Products under Development by Companies 12

4.1 Metered Dose Inhaler Devices Companies-Pipeline Products by Stage of Development 12

4.2 Metered Dose Inhaler Devices-Pipeline Products by Stage of Development 13

5 Metered Dose Inhaler Devices Companies and Product Overview 14

5.1 Aerophase Inc Company Overview 14

5.1.1 Aerophase Inc Pipeline Products & Ongoing Clinical Trials Overview 14

5.2 Circassia Pharmaceuticals Plc Company Overview 15

5.2.1 Circassia Pharmaceuticals Plc Pipeline Products & Ongoing Clinical Trials Overview 15

5.3 Globe Medical Tech Inc Company Overview 19

5.3.1 Globe Medical Tech Inc Pipeline Products & Ongoing Clinical Trials Overview 19

5.4 Lab Automate Technologies Inc Company Overview 20

5.4.1 Lab Automate Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 20

5.5 Medicom Innovation Partner a/s Company Overview 21

5.5.1 Medicom Innovation Partner a/s Pipeline Products & Ongoing Clinical Trials Overview 21

5.6 Min USA LLC Company Overview 22

5.6.1 Min USA LLC Pipeline Products & Ongoing Clinical Trials Overview 22

5.7 Mylan NV Company Overview 23

5.7.1 Mylan NV Pipeline Products & Ongoing Clinical Trials Overview 23

5.8 Propeller Health Company Overview 24

5.8.1 Propeller Health Pipeline Products & Ongoing Clinical Trials Overview 24

5.9 Rensselaer Polytechnic Institute Company Overview 25

5.9.1 Rensselaer Polytechnic Institute Pipeline Products & Ongoing Clinical Trials Overview 25

5.10 Vectura Group Plc Company Overview 26

5.10.1 Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview 26

5.11 Verona Pharma Plc Company Overview 28

5.11.1 Verona Pharma Plc Pipeline Products & Ongoing Clinical Trials Overview 28

6 Metered Dose Inhaler Devices- Recent Developments 29

6.1 May 17, 2017: Teva Showcases Asthma Research at the 2017 American Thoracic Society International Conference 29

6.2 May 10, 2017: Mylan Reports First Quarter 2017 Results 30

6.3 May 08, 2017: Dr. Stephen S. Lane joins Alcon as Chief Medical Officer and Global Head Franchise Clinical Strategy 32

6.4 May 02, 2017: Merck Announces First-Quarter 2017 Financial Results 32

6.5 May 01, 2017: Mylan Nominates Sjoerd Vollebregt for Election to Board of Directors 34

6.6 Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued 35

6.7 Apr 10, 2017: Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors 39

6.8 Apr 06, 2017: Merck Receives 2017 ENERGY STAR Sustained Excellence Award from U. S. Environmental Protection Agency 40

6.9 Mar 31, 2017: City Of Austin Announces Merck Economic Development Proposal 40

6.10 Mar 28, 2017: Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer 41

6.11 Mar 21, 2017: Vectura Group: Preliminary Results for the nine-month period ended 31 December 2016 42

6.12 Mar 21, 2017: Vectura Group Announces Preliminary Results for the nine-month period ended 31 December 2016 43

6.13 Mar 06, 2017: Vectura Group: Board Change 44

6.14 Mar 01, 2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance 45

6.15 Feb 28, 2017: Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting 47

6.16 Feb 16, 2017: Vectura achieves GBP9 million royalty cap from GSK Ellipta products 48

6.17 Feb 02, 2017: Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results 49

6.18 Jan 26, 2017: Symbicort granted paediatric exclusivity in the US 51

6.19 Jan 26, 2017: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report 51

6.20 Jan 26, 2017: Achievement of sales milestone for COPD products 52

6.21 Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback 53

6.22 Jan 25, 2017: Daktari Achieves Milestone in Its Merck HCV Collaboration 60

6.23 Jan 11, 2017: Vectura Group: Pre-close update 60

6.24 Dec 21, 2016: Symbicort Maintenance And Reliever Therapy (SMART) now available for adolescents in the UK offering patient-adjusted asthma treatment 61

6.25 Dec 14, 2016: Consort Medical: Directorate Change 63

6.26 Dec 06, 2016: Consort Medical Reports Interim Results Results For The Six Months Ended 31 October 2016 63

6.27 Dec 01, 2016: Aptar Pharma Nears Completion Of Elastomer Component Capacity In North America 65

6.28 Nov 29, 2016: Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda 66

6.29 Nov 25, 2016: Consort Medical: CFO Appointment 67

6.30 Nov 09, 2016: Mylan Reports Third Quarter 2016 Results 67

6.31 Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters 72

6.32 Oct 25, 2016: Merck Announces Third-Quarter 2016 Financial Results 79

6.33 Sep 07, 2016: New Scale-Up and Commercial Supply Agreement 82

6.34 Aug 17, 2016: Consort Medical Announces Directorate Change 82

6.35 Aug 09, 2016: Mylan Reports Strong Second Quarter 2016 Results Including Total Revenues Up 8% 83

6.36 Aug 03, 2016: Boehringer Ingelheim: Growth in all core businesses 86

6.37 Jul 19, 2016: Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects 88

6.38 Jul 08, 2016: Dr John Brown, Non-Executive Director, confirms date to step down 94

6.39 Jul 04, 2016: Marco Filippini Appointed Vice Coordinator of the Italian Biosimilars Group 94

6.40 Jun 16, 2016: Consort Medical Announces Final results For The Year Ended 30 April 2016 95

6.41 Jun 10, 2016: Vectura Group announces Directorate Changes 104

6.42 Jun 10, 2016: Simone Menne-new Member of the Board of Managing Directors of Boehringer Ingelheim/Responsible for Corporate Board Division Finance 104

6.43 Jun 08, 2016: Merck Expands its Investment Fund Merck Ventures 105

6.44 May 26, 2016: Vectura Group-Preliminary Results for twelve months ending 31 March 2016 105

6.45 May 25, 2016: Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event 113

6.46 May 24, 2016: COTA Increases Cross-Industry Support With the Addition of Celgene, Foundation Medicine HealthScape Advisors and Novartis as Strategic Investors 114

7 Appendix 116

7.1 Methodology 116

7.2 About GlobalData 119

7.3 Contact Us 119

7.4 Disclaimer 119

1.2 List of Figures

Figure 1: Metered Dose Inhaler Devices-Pipeline Products by Stage of Development 7

Figure 2: Metered Dose Inhaler Devices-Pipeline Products by Territory 8

Figure 3: Metered Dose Inhaler Devices-Pipeline Products by Regulatory Path 9

Figure 4: Metered Dose Inhaler Devices-Pipeline Products by Estimated Approval Date 10

Figure 5: Metered Dose Inhaler Devices-Ongoing Clinical Trials 11

1.1 List of Tables

Table 1: Metered Dose Inhaler Devices-Pipeline Products by Stage of Development 7

Table 2: Metered Dose Inhaler Devices-Pipeline Products by Territory 8

Table 3: Metered Dose Inhaler Devices-Pipeline Products by Regulatory Path 9

Table 4: Metered Dose Inhaler Devices-Pipeline Products by Estimated Approval Date 10

Table 5: Metered Dose Inhaler Devices-Ongoing Clinical Trials 11

Table 6: Metered Dose Inhaler Devices Companies-Pipeline Products by Stage of Development 12

Table 7: Metered Dose Inhaler Devices-Pipeline Products by Stage of Development 13

Table 8: Aerophase Inc Pipeline Products & Ongoing Clinical Trials Overview 14

Table 9: Metered Dose Inhaler-Product Status 14

Table 10: Metered Dose Inhaler-Product Description 14

Table 11: Circassia Pharmaceuticals Plc Pipeline Products & Ongoing Clinical Trials Overview 15

Table 12: Fliveo-Product Status 15

Table 13: Fliveo-Product Description 15

Table 14: Fluticasone propionate/Salmeterol xinafoate pMDI-Product Status 16

Table 15: Fluticasone propionate/Salmeterol xinafoate pMDI-Product Description 16

Table 16: Circassia Pharmaceuticals Plc-Ongoing Clinical Trials Overview 17

Table 17: Fluticasone propionate/Salmeterol xinafoate pMDI-A Phase III Registration Study of Seretide Substitute (PSX2005) 18

Table 18: Fluticasone propionate/Salmeterol xinafoate pMDI-An Exploratory, Single-center, Single-dose, Open-label, Randomized, Three-way Crossover Study to Investigate the Pharmacokinetics of Three Orally Inhaled Formulations Containing Fluticasone Propionate and Salmeterol (as Xinafoate) 50/25 mcg Per Actuation Administered From a Pressurized Metered Dose Inhaler, in at Least 24 Healthy Male and Female Subjects 18

Table 19: Globe Medical Tech Inc Pipeline Products & Ongoing Clinical Trials Overview 19

Table 20: Inhaler-Product Status 19

Table 21: Inhaler-Product Description 19

Table 22: Lab Automate Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 20

Table 23: Ultrasonic Metered Dose Inhaler-Product Status 20

Table 24: Ultrasonic Metered Dose Inhaler-Product Description 20

Table 25: Medicom Innovation Partner a/s Pipeline Products & Ongoing Clinical Trials Overview 21

Table 26: Asmair-Product Status 21

Table 27: Asmair-Product Description 21

Table 28: Min USA LLC Pipeline Products & Ongoing Clinical Trials Overview 22

Table 29: Envi-Product Status 22

Table 30: Envi-Product Description 22

Table 31: Mylan NV Pipeline Products & Ongoing Clinical Trials Overview 23

Table 32: Metered Dose Inhaler-Product Status 23

Table 33: Metered Dose Inhaler-Product Description 23

Table 34: Propeller Health Pipeline Products & Ongoing Clinical Trials Overview 24

Table 35: Connected Metered Dose Inhaler-Product Status 24

Table 36: Connected Metered Dose Inhaler-Product Description 24

Table 37: Rensselaer Polytechnic Institute Pipeline Products & Ongoing Clinical Trials Overview 25

Table 38: Bloom Inhaler-Product Status 25

Table 39: Bloom Inhaler-Product Description 25

Table 40: Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview 26

Table 41: Flutiform HFA-MDI-Product Status 26

Table 42: Flutiform HFA-MDI-Product Description 26

Table 43: Flutiform K-Haler-Product Status 27

Table 44: Flutiform K-Haler-Product Description 27

Table 45: Verona Pharma Plc Pipeline Products & Ongoing Clinical Trials Overview 28

Table 46: RPL554-Metered Dose Inhaler-Product Status 28

Table 47: RPL554-Metered Dose Inhaler-Product Description 28

Table 48: Glossary 117

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aerophase Inc, Circassia Pharmaceuticals Plc, Globe Medical Tech Inc, Lab Automate Technologies Inc, Medicom Innovation Partner a/s, Min USA LLC, Mylan NV, Propeller Health, Rensselaer Polytechnic Institute, Vectura Group Plc, Verona Pharma Plc

Inhaler; Medicom Innovation Partner a/s, Asmair; Min USA LLC, Envi; Mylan NV, Metered Dose Inhaler; Propeller Health, Connected Metered Dose Inhaler; Rensselaer Polytechnic Institute, Bloom Inhaler; Vectura Group Plc, Flutiform HFA-MDI; Vectura Group Plc, Flutiform K-Haler; Verona Pharma Plc, RPL554-Metered Dose Inhaler

select a license

Single User License
USD 2500 INR 162250
Site License
USD 5000 INR 324500
Corporate User License
USD 7500 INR 486750

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com